Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss(Novartis (China)), Saskia M. Brachmann(Novartis (Switzerland)), Catherine Leblanc(Novartis (Switzerland)), Ruben de Kanter(Novartis (Switzerland)), Christian Schnell(Novartis (Switzerland)), Claudio Bomio-Confaglia(Novartis (Switzerland)), Lekshmi Dharmarajan(Novartis (Switzerland)), Kim S. Beyer(Genomics Institute of the Novartis Research Foundation), Helen Oakman(American Institutes for Research), Peter Wessels(Novartis (Switzerland)), Carmine Fedele(American Institutes for Research), Frédéric J. Zécri(American Institutes for Research), Toshio Shimizu(Wakayama Medical University), Johannes Ottl(Novartis (Switzerland)), Pascal Rigollier(Novartis (Switzerland)), Victoria Head(Novartis (Switzerland)), Jason Murphy(American Institutes for Research), Rainer Wilcken(Novartis (Switzerland)), Eloísa Jiménez Núñez(Novartis (Switzerland)), Heather Burks(American Institutes for Research), Hans Voshol(Novartis (Switzerland)), Rowan Stringer(Novartis (Switzerland)), Edwige Lorthiois(Novartis (Switzerland)), Anna F. Farago(Massachusetts General Hospital), Richard Sedrani(Novartis (Switzerland)), Nils Ostermann(Novartis (Switzerland)), Andrea Vaupel(Novartis (Switzerland)), Xiaoming Cui(Novartis (United States)), Marc Gerspacher(Novartis (Switzerland)), Ashley Jaeger(American Institutes for Research), Louise Barys(Novartis (Switzerland)), Simona Cotesta(Novartis (Switzerland)), Sauveur-Michel Maira(Novartis (Switzerland)), Daniel Guthy(Novartis (Switzerland)), Toni Widmer(Novartis (Switzerland)), Xueying Chen(Novartis (United States)), Jeffrey D. Kearns(American Institutes for Research), Kun Xu(Novartis (United States)), Danielle Roman(Novartis (Switzerland))
Cited by 134
Related Papers
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity
|Molecular Cancer Therapeutics|2008|1.1k
E-CELL: software environment for whole-cell simulation.
|Bioinformatics|1999|765
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670